JPH06340577A - 13c-labeled eicosapentaenoic acid, its derivative and production thereof - Google Patents
13c-labeled eicosapentaenoic acid, its derivative and production thereofInfo
- Publication number
- JPH06340577A JPH06340577A JP5065734A JP6573493A JPH06340577A JP H06340577 A JPH06340577 A JP H06340577A JP 5065734 A JP5065734 A JP 5065734A JP 6573493 A JP6573493 A JP 6573493A JP H06340577 A JPH06340577 A JP H06340577A
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- acid
- icosapentaenoic acid
- icosapentaenoic
- eicosapentaenoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 47
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 46
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract description 8
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 16
- 239000012138 yeast extract Substances 0.000 claims abstract description 16
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000002372 labelling Methods 0.000 abstract description 18
- 244000005700 microbiome Species 0.000 abstract description 7
- 239000001963 growth medium Substances 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- NDWBPPVTFNMEBT-UHFFFAOYSA-N methyl icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC NDWBPPVTFNMEBT-UHFFFAOYSA-N 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000556533 uncultured marine bacterium Species 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000863432 Shewanella putrefaciens Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000011734 sodium Chemical class 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は13C標識イコサペンタエ
ン酸とその誘導体に関するものである。13C標識イコサ
ペンタエン酸は安全な標識化合物として医学、薬学、生
理学、生化学などにおけるトレーサ実験等に極めて有用
である。FIELD OF THE INVENTION The present invention relates to 13 C-labeled icosapentaenoic acid and its derivatives. 13 C-labeled icosapentaenoic acid is extremely useful as a safe labeling compound for tracer experiments in medicine, pharmacy, physiology, biochemistry and the like.
【0002】[0002]
【従来の技術】イコサペンタエン酸はn−3の高度不飽
和脂肪酸としてn−6の高度不飽和脂肪酸由来のイコサ
ノイドに拮抗して血小板凝集抑制作用、血中脂質低下作
用、抗炎症作用、抗腫瘍作用等の薬理作用を示し、体の
ホメオスタシスに重要であることが認められている。こ
のような作用を有しているイコサペンタエン酸は主に細
胞膜リン脂質や脂肪組織中に存在しており、ミトコンド
リアやペルオキシゾームのβ酸化分解系に入ってアセチ
ルCoAまで分解されるか、鎖長延長と不飽和化を受け
同じn−3のドコサヘキサエン酸に変換される等の代謝
を受ける。最近ではペルオキシゾームの長鎖脂肪酸のβ
酸化分解活性測定が疾患の診断にも使用される可能性も
示唆されている。BACKGROUND OF THE INVENTION Icosapentaenoic acid, as a highly unsaturated fatty acid of n-3, antagonizes an icosanoid derived from a highly unsaturated fatty acid of n-6 to suppress platelet aggregation, lower lipid in blood, anti-inflammatory action, antitumor action. It has been recognized that it is important for body homeostasis. Icosapentaenoic acid, which has such an effect, is mainly present in cell membrane phospholipids and adipose tissue, and enters the β-oxidative degradation system of mitochondria and peroxisomes to be degraded to acetyl-CoA, or chain length extension. And undergoes metabolism such as being desaturated and converted into the same n-3 docosahexaenoic acid. Recently, β of long-chain fatty acid of peroxisome
It has also been suggested that the oxidative degradation activity measurement may be used for diagnosis of diseases.
【0003】このような代謝系が必要に応じて正常に働
くことが人の健康にとって必要であるので、イコサペン
タエン酸のインビボ(in vivo)における代謝を直接調
べることは重要な意義を持つ。このためイコサペンタエ
ン酸を同位体で標識しておく必要がある。しかしなが
ら、現在得られているイコサペンタエン酸の標識化合物
は、1位の炭素が炭素14(14C)に置換された放射性
同位体標識であり、β酸化分解系の代謝は原理的にトレ
ーサーできない。また、人のインビボ(in vivo)実験
では放射性同位体は危険を伴い日本では法律で禁止され
ている。従って、人体を危険に晒すことのない安定同位
体でユニフォーマルに標識されたイコサペンタエン酸の
提供が望まれている。さらにその他の高級脂肪酸に関し
ても同様の理由により安定同位体ユニフォーム標識化合
物が必要とされている。Since it is necessary for human health that such a metabolic system normally operates as needed, it is important to directly investigate the in vivo metabolism of icosapentaenoic acid. Therefore, it is necessary to label icosapentaenoic acid with an isotope. However, the currently obtained labeling compound of icosapentaenoic acid is a radioisotope label in which the carbon at the 1-position is replaced by carbon 14 ( 14 C), and the metabolism of β-oxidative decomposition system cannot be traced in principle. In addition, radioactive isotopes are dangerous in humans in vivo experiments and are prohibited by law in Japan. Therefore, it is desired to provide icosapentaenoic acid, which is uniformly labeled with a stable isotope that does not endanger the human body. Further, for other higher fatty acids, stable isotope uniform labeled compounds are required for the same reason.
【0004】一方、多くの生物の脂肪酸合成経路は主に
アセチル−CoA又はアセチル−ACPをプライマーと
してマロニル−CoA又はマロニル−ACPの縮合によ
って脂肪酸鎖が延びて行くことが知られており(生化学
実験講座9 脂質の代謝 東京化学同人1975)、安
定同位体標識酢酸ナトリウムを培地に添加することによ
って生成した重水素(2D)又は13C標識オレイン酸が
立体化学の研究に用いられている(K.Arai et.al. J.A
m.Chem.Soc. 1989, 111,3391-3399.)。この事は重水素
標識及び/又は13C標識高級脂肪酸の調整が重水素中及
び/又は13C標識酢酸ナトリウム含有培地で生物を生育
させることによって可能であることを示している。さら
に、13Cの12Cに対する同位体効果は、重水素の水素に
対する同位体効果に比べて小さいので、一般に13C標識
化合物の方が重水素標識化合物よりもトレーサー実験の
結果はより正確であるといえる。On the other hand, it is known that the fatty acid synthesis pathways of many organisms mainly extend the fatty acid chain by condensation of malonyl-CoA or malonyl-ACP using acetyl-CoA or acetyl-ACP as a primer (biochemistry Laboratory Lecture 9 Metabolism of Lipids Tokyo Kagaku Dojin (1975), deuterium ( 2 D) or 13 C-labeled oleic acid produced by adding stable isotope-labeled sodium acetate to the medium is used for stereochemical studies ( K.Arai et.al. JA
m. Chem. Soc. 1989, 111, 3391-3399.). This indicates that preparation of deuterium-labeled and / or 13 C-labeled higher fatty acids is possible by growing the organism in deuterium and / or in a medium containing 13 C-labeled sodium acetate. Furthermore, since the isotope effect of 13 C on 12 C is smaller than that of deuterium on hydrogen, 13 C-labeled compounds generally give more accurate tracer experiment results than deuterium-labeled compounds. Can be said.
【0005】[0005]
【発明が解決しようとする課題】上述したように、13C
標識酢酸ナトリウムを含有する培地で生物を生育させる
ことによって13C標識高級脂肪酸の生産が可能であり、
適宜なイコサペンタエン酸産生菌を用いることによって
13C標識イコサペンタエン酸の生産も可能であるが、従
来の13C標識高級脂肪酸の製造方法にあっては、一般に
用いる培地に13C標識酢酸ナトリウムを添加しているの
で、培養した微生物等から得られる13C標識高級脂肪酸
の全炭素原子に占める13C原子の存在比(以下、13C標
識化率という)は多くても50%程度であり、それより
高い13C標識化率を得るべく培地中の炭素源に占める13
C標識酢酸ナトリウムの割合を多くすると、イコサペン
タエン酸を生産する微生物の増殖が低下してしまうため
に、13C標識化率が90%以上の13C標識イコサペンタ
エン酸の生産は事実上不可能であった。As described above, as described above, 13 C
It is possible to produce 13 C-labeled higher fatty acid by growing the organism in a medium containing labeled sodium acetate,
By using an appropriate icosapentaenoic acid-producing bacterium
It is possible to produce 13 C-labeled icosapentaenoic acid, but in the conventional method for producing 13 C-labeled higher fatty acid, since 13 C-labeled sodium acetate is added to a commonly used medium, it can be obtained from cultured microorganisms or the like. The abundance ratio of 13 C atoms to the total carbon atoms of the 13 C-labeled higher fatty acids (hereinafter referred to as 13 C labeling rate) is about 50% at most, and the medium has a higher 13 C labeling rate. 13 of total carbon source
If the proportion of C-labeled sodium acetate is increased, the growth of microorganisms that produce icosapentaenoic acid is reduced, and it is practically impossible to produce 13 C-labeled icosapentaenoic acid having a 13 C-labeling rate of 90% or more. It was
【0006】本発明は上記事情に鑑みてなされたもの
で、その目的は、有益な薬理作用を有するイコサペンタ
エン酸の人体のインビボ(in vivo)実験を含めた広範
囲な代謝実験および代謝能力の測定等に極めて有用な、
高い13C標識化率で標識された13C標識イコサペンタエ
ン酸またはそのエステル等の誘導体を提供することにあ
る。The present invention has been made in view of the above circumstances, and an object thereof is a wide range of metabolic experiments including measurement of the metabolic ability of icosapentaenoic acid, which has a beneficial pharmacological action, including in vivo experiments in humans. Extremely useful for,
It is intended to provide a derivative such as 13 C-labeled icosapentaenoic acid or its ester labeled with a high 13 C-labeling rate.
【0007】[0007]
【課題を解決するための手段】本発明に係る13C標識イ
コサペンタエン酸は、全炭素原子に占める13C原子の存
在比が95%以上であることを特徴としている。また本
発明においては該13C標識イコサペンタエン酸の誘導体
も包含している。The 13 C-labeled icosapentaenoic acid according to the present invention is characterized in that the abundance ratio of 13 C atoms in all carbon atoms is 95% or more. The present invention also includes the 13 C-labeled icosapentaenoic acid derivative.
【0008】また本発明に係る13C標識イコサペンタエ
ン酸の製造方法は、全炭素原子に占める13C原子の存在
比が95%以上である13C標識酵母エキス又は該酵母エ
キスと13C標識有機化合物とを含む培地を用いてイコサ
ペンタエン酸産生菌を培養し、ついで該培養菌体から13
C標識イコサペンタエン酸またはその誘導体を分離する
ことを特徴としている。Further, the method for producing 13 C-labeled icosapentaenoic acid according to the present invention comprises a 13 C-labeled yeast extract or a yeast extract and a 13 C-labeled organic compound in which the abundance ratio of 13 C atoms to all carbon atoms is 95% or more. The icosapentaenoic acid-producing bacterium is cultured in a medium containing and then 13
The method is characterized in that C-labeled icosapentaenoic acid or its derivative is separated.
【0009】本発明に係る13C標識イコサペンタエン酸
は、13C標識化率が95%以上あることを特徴としてい
る。この13C標識イコサペンタエン酸における炭素以外
の構成元素である酸素と水素については特に限定され
ず、通常の酸素(16O)や水素1H)であるが、これら
を安定同位体である重水素,17O,18Oで標識すること
も可能である。The 13 C-labeled icosapentaenoic acid according to the present invention is characterized by having a 13 C labeling rate of 95% or more. Oxygen and hydrogen, which are the constituent elements other than carbon in 13 C-labeled icosapentaenoic acid, are not particularly limited, and are ordinary oxygen ( 16 O) and hydrogen 1 H). It is also possible to label with 17 O or 18 O.
【0010】また本発明においては13C標識イコサペン
タエン酸の誘導体も包含している。その誘導体として
は、13C標識イコサペンタエン酸のメチルエステルやエ
チルエステル等の低級アルコールとのエステル、高級ア
ルコールとのエステル、グリセリンとのエステル、グリ
コールとのエステル、ステロールとのエステル、糖アル
コールとのエステル等のエステル類、酸塩化物、Na塩
やK塩等が挙げられる。The present invention also includes derivatives of 13 C-labeled icosapentaenoic acid. Examples of the derivative include ester with lower alcohol such as methyl ester or ethyl ester of 13 C-labeled icosapentaenoic acid, ester with higher alcohol, ester with glycerin, ester with glycol, ester with sterol, ester with sugar alcohol. And the like, acid chlorides, Na salts, K salts and the like.
【0011】また本発明に係る13C標識イコサペンタエ
ン酸の製造方法において用いられる微生物としては、イ
コサペンタエン酸を生産する微生物であればどのような
微生物でも良い。例えばイコサペンタエン酸産生海洋細
菌であるシーワネラ・ピュートリファシエンス SCR
C−2874(FERMBP−1625)、アルテロモ
ナス・ピュートリファシエンス SCRC−2871
(FERMBP−1624)、シュードモナス・ピュー
トリファシエンス SCRC−2878(FERMBP
−1623)等、イコサペンタエン酸の前駆体を添加し
た培地或いは低温で培養した場合のアラキドン酸産生糸
状菌である、モルティエレラ・アルピナ(IFO 85
68)などが挙げられる。The microorganism used in the method for producing 13 C-labeled icosapentaenoic acid according to the present invention may be any microorganism as long as it produces icosapentaenoic acid. For example, Shiwanella putrefaciens SCR, which is a marine bacterium producing icosapentaenoic acid.
C-2874 (FERMBP-1625), Alteromonas putrifaciens SCRC-2871
(FERMBP-1624), Pseudomonas putrifaciens SCRC-2878 (FERMBP
-1623) and the like, Mortierella alpina (IFO 85, which is an arachidonic acid-producing filamentous fungus when cultured at a medium added with a precursor of icosapentaenoic acid or at a low temperature).
68) and the like.
【0012】これらイコサペンタエン酸を産生する微生
物の培地としては、13C標識酵母エキス又は該酵母エキ
スと13C標識有機化合物を用いることができる。13C標
識酵母エキスは13C標識有機化合物を炭素源として培地
で酵母を培養することにより得られるもので、13C標識
化率が95%以上のものも得られる。13C標識有機化合
物としては、直接或いは代謝生産物として間接的に脂肪
酸合成に関与する化合物であればいずれでもよくそれら
の化合物は市販品として容易に入手可能であり、例え
ば、酢酸ナトリウム、キシロース、グルコース等の糖
類、アラニン、アスパラギン酸等のアミノ酸が使用でき
る。培養は、例えば、海洋細菌では13C標識アミノ酸混
合物1重量%、13C標識酵母エキス0.5重量%を1/
2濃度の人工海水に溶解した培地(pH7.0)や、13
C標識酵母エキス1重量%を1/2濃度の人工海水に溶
解した培地(pH7.0)が用いられる。As a medium for these microorganisms producing icosapentaenoic acid, 13 C-labeled yeast extract or the yeast extract and 13 C-labeled organic compound can be used. The 13 C-labeled yeast extract is obtained by culturing yeast in a medium using a 13 C-labeled organic compound as a carbon source, and a 13 C-labeling rate of 95% or more can also be obtained. The 13 C-labeled organic compound may be any compound that directly or indirectly participates in fatty acid synthesis as a metabolite, and those compounds are easily available as commercial products, and examples thereof include sodium acetate, xylose, Sugars such as glucose and amino acids such as alanine and aspartic acid can be used. For example, 1% by weight of a 13 C-labeled amino acid mixture for marine bacteria and 0.5% by weight of 13 C-labeled yeast extract were used for culturing.
Medium (pH 7.0) dissolved in 2 concentrations of artificial seawater, 13
A medium (pH 7.0) in which 1% by weight of C-labeled yeast extract is dissolved in 1/2 concentration of artificial seawater is used.
【0013】このような培地で培養された菌体を凍結乾
燥後、常法により塩酸メタノールあるいはナトリウムメ
チラート等でメチルエステル化またはエチルエステル化
すると、菌体中のあらゆる脂肪酸誘導体の脂肪酸組成を
GC−MSで分析できる。また、湿菌体あるいは乾燥菌
体を適当な有機溶剤等を用いて抽出し、シリカゲルTL
Cにて脂質を分画した後、各々の脂質の構成脂肪酸を同
様にして分析できる。上述の方法により培養した本発明
の脂肪酸の13C標識化率は、ほぼ100%である。上述
の方法によりエステル化された13C標識イコサペンタエ
ン酸は常法にしたがって、ケン化およびそれに引き続く
酸性化によって遊離型に誘導できる。またこの13C標識
イコサペンタエン酸は必要に応じて種々のアルコールと
のエステル化などを行うことによって種々の誘導体を合
成することができる。13C標識イコサペンタエン酸は常
法に従い逆相PLCおよび硝酸銀処理シリカゲルや硝酸
銀処理シリカゲルTLCを組み合わせることによって、
同時に生成する高度不飽和脂肪酸から各々を単離でき
る。After freeze-drying the cells cultured in such a medium and then methyl-esterifying or ethyl-esterifying them with methanol such as hydrochloric acid methanol or sodium methylate, the fatty acid composition of all fatty acid derivatives in the cells is GC. -Can be analyzed by MS. In addition, wet or dry bacterial cells are extracted with an appropriate organic solvent or the like to obtain silica gel TL.
After fractionating the lipids at C, the constituent fatty acids of each lipid can be similarly analyzed. The 13 C-labeling rate of the fatty acid of the present invention cultivated by the above method is almost 100%. The 13 C-labeled icosapentaenoic acid esterified by the method described above can be derivatized to the free form by saponification and subsequent acidification according to a conventional method. Also, various derivatives of this 13 C-labeled icosapentaenoic acid can be synthesized by subjecting it to esterification with various alcohols as necessary. 13 C-labeled icosapentaenoic acid can be prepared by combining reverse-phase PLC and silver nitrate-treated silica gel or silver nitrate-treated silica gel TLC according to a conventional method.
Each can be isolated from the polyunsaturated fatty acids that are produced simultaneously.
【0014】[0014]
【実施例】1/2濃度の人工海水に13C標識酵母エキス
1重量%を溶解した培地50mlに、イコサペンタエン
酸産生海洋細菌のシーワネラ・ピュートリファシエンス
(FERMBP−1625)を植菌し、10℃の温度下
で振とう培養した。対数増殖期後期で集菌し、分離した
培養菌体に凍結乾燥を行い、84mgの乾燥菌体を得
た。この菌体を6mlの塩酸メタノールに懸濁し、80
℃、1時間加熱した後、n-ヘキサンで抽出し、約15
mgの脂肪酸メチルエステル混合物を得た。抽出した脂
肪酸メチルエステル混合物を硝酸銀処理シリカゲルTL
Cで精製し、約200μgのイコサペンタエン酸メチル
エステルを得た。得られたイコサペンタエン酸メチルエ
ステルをGC−MSで分析した。その分析結果を図1に
示した。その結果、13Cで標識していない天然のイコサ
ペンタエン酸メチルエステルの場合、親イオンのM/Z
は316であるのに対し、本例で得られたイコサペンタ
エン酸メチルエステル(13C標識イコサペンタエン酸メ
チルエステル)の親イオンのM/Zは336に唯一のピ
ークが見られた。この結果13C標識化率は99%以上と
見積もられた。[Examples] 50 ml of a medium prepared by dissolving 1% by weight of 13 C-labeled yeast extract in 1/2 concentration artificial seawater was inoculated with Shiwanella putrifaciens (FERMBP-1625), which is a marine bacterium producing icosapentaenoic acid, and 10 The cells were shake-cultured at a temperature of ° C. The cells were collected in the late logarithmic growth phase, and the separated cultured cells were freeze-dried to obtain 84 mg of dried cells. The cells were suspended in 6 ml of hydrochloric acid methanol,
After heating at ℃ for 1 hour, extract with n-hexane,
mg of fatty acid methyl ester mixture was obtained. Extracted fatty acid methyl ester mixture with silver nitrate treated silica gel TL
Purification by C gave approximately 200 μg of icosapentaenoic acid methyl ester. The obtained icosapentaenoic acid methyl ester was analyzed by GC-MS. The analysis result is shown in FIG. As a result, in the case of natural icosapentaenoic acid methyl ester not labeled with 13 C, the parent ion M / Z
Is 316, whereas M / Z of the parent ion of icosapentaenoic acid methyl ester ( 13 C-labeled icosapentaenoic acid methyl ester) obtained in this example has a unique peak at 336. As a result, the 13 C labeling rate was estimated to be 99% or more.
【0015】[0015]
【発明の効果】以上説明したように、本発明に係る13C
標識イコサペンタエン酸は、13C標識化率が95%以上
あるものなので、人体を危険に晒すことなく安全に使用
でき、標識化率が高いことによって核磁気共鳴スペクト
ル法やGC−MS法などにより高精度で検出することが
できる。また高い標識化率でユニフォーマルに標識され
ているので、人体のインビボ(in vivo)実験を含めた
広範囲な代謝実験および代謝能力についても高精度で測
定が可能となる。As described above, 13 C according to the present invention
Labeled icosapentaenoic acid has a 13 C labeling rate of 95% or more, so it can be used safely without endangering the human body. Due to its high labeling rate, it can be highly labeled by nuclear magnetic resonance spectroscopy or GC-MS. It can be detected with accuracy. Further, since it is uniformly labeled with a high labeling rate, it is possible to measure a wide range of metabolic experiments and metabolic ability including in vivo experiments on the human body with high accuracy.
【0016】また本発明に係る製造方法では、13C標識
率95%以上である13C標識酵母エキス又は該酵母エキ
スと13C標識有機化合物とを含む培地を用いてイコサペ
ンタエン酸生産菌を培養することにより、従来法では不
可能であった13C標識化率が95%以上の13C標識イコ
サペンタエン酸の生産が可能となる。しかも、13C標識
酵母エキスを培地に用いることによって、イコサペンタ
エン酸生産菌の増殖率を高めることができ、13C標識化
率が95%以上の13C標識イコサペンタエン酸を効率良
く生産することができる。In the production method according to the present invention, the icosapentaenoic acid-producing bacterium is cultured using a 13 C-labeled yeast extract having a 13 C-labeling rate of 95% or more or a medium containing the yeast extract and a 13 C-labeled organic compound. As a result, it becomes possible to produce 13 C-labeled icosapentaenoic acid having a 13 C-labeling rate of 95% or more, which was impossible by the conventional method. Moreover, by using 13 C-labeled yeast extract to the medium, it is possible to increase the growth rate of eicosapentaenoic acid producing bacteria, 13 C-labeled rate can efficiently produce 95% of the 13 C-labeled eicosapentaenoic acid .
【図面の簡単な説明】[Brief description of drawings]
【図1】本発明の実施例で製造した13C標識イコサペン
タエン酸メチルエステルのマススペクトルである。FIG. 1 is a mass spectrum of 13 C-labeled icosapentaenoic acid methyl ester prepared in an example of the present invention.
Claims (2)
95%以上であることを特徴とする13C標識イコサペン
タエン酸とその誘導体。1. A 13 C-labeled icosapentaenoic acid and a derivative thereof, wherein the abundance ratio of 13 C atoms to all carbon atoms is 95% or more.
95%以上である13C標識酵母エキス又は該酵母エキス
と13C標識有機化合物とを含む培地を用いてイコサペン
タエン酸産生菌を培養し、ついで該培養菌体から13C標
識イコサペンタエン酸またはその誘導体を分離すること
を特徴とする13C標識イコサペンタエン酸の製造方法。2. An icosapentaenoic acid-producing bacterium is cultivated using a 13 C-labeled yeast extract or a medium containing the yeast extract and a 13 C-labeled organic compound in which the abundance ratio of 13 C atoms to all carbon atoms is 95% or more. Then, 13 C-labeled icosapentaenoic acid or a derivative thereof is separated from the cultured cells, and a method for producing 13 C-labeled icosapentaenoic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5065734A JPH06340577A (en) | 1993-03-24 | 1993-03-24 | 13c-labeled eicosapentaenoic acid, its derivative and production thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5065734A JPH06340577A (en) | 1993-03-24 | 1993-03-24 | 13c-labeled eicosapentaenoic acid, its derivative and production thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06340577A true JPH06340577A (en) | 1994-12-13 |
Family
ID=13295553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5065734A Withdrawn JPH06340577A (en) | 1993-03-24 | 1993-03-24 | 13c-labeled eicosapentaenoic acid, its derivative and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH06340577A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013099365A (en) * | 2000-01-19 | 2013-05-23 | Dsm Ip Assets Bv | Solventless extraction process |
-
1993
- 1993-03-24 JP JP5065734A patent/JPH06340577A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013099365A (en) * | 2000-01-19 | 2013-05-23 | Dsm Ip Assets Bv | Solventless extraction process |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
El Boustani et al. | Direct in vivo characterization of delta 5 desaturase activity in humans by deuterium labeling: effect of insulin | |
US5466434A (en) | Method of diagnosing fatty acid metabolism or absorption disorders using labeled triglyceride oils produced by cultivation of microorganisms | |
Chilton et al. | Metabolic fate of platelet-activating factor in neutrophils. | |
Pettitt et al. | Synthesis of lipoxins and other lipoxygenase products by macrophages from the rainbow trout, Oncorhynchus mykiss | |
Nishida et al. | Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. | |
Blaner | Cellular metabolism and actions of 13-cis-retinoic acid | |
Meyer et al. | Lipid metabolism in the larval and adult forms of the tapeworm Spirometra mansonoides | |
Pawlosky et al. | Essential fatty acid uptake and metabolism in the developing rodent brain | |
Bade et al. | Cholesterol esters of the cockroach Eurycotis floridana | |
Birkle et al. | Effect of K+ depolarization on the synthesis of prostaglandins and hydroxyeicosatetra (5, 8, 11, 14) enoic acids (HETE) in the rat retina: Evidence for esterification of 12-HETE in lipids | |
Baer et al. | Free and esterified 13 (R, S)-hydroxyoctadecadienoic acids: principal oxygenase products in psoriatic skin scales. | |
Walker et al. | The positional distribution of fatty acids in the phospholipids and triglycerides of Mycobacterium smegmatis and M. bovis BCG | |
Brossard et al. | Stable isotope tracer and gas-chromatography combustion isotope ratio mass spectrometry to study the in vivo compartmental metabolism of docosahexaenoic acid | |
JPH10291955A (en) | 13c-labeled docosahexaenoic acid and its production | |
Puhvel | Esterification of [4-14C] cholesterol by cutaneous bacteria (Staphylococcus epidermidis, Propionibacterium acnes, and Propionibacterium granulosum) | |
JPH06340577A (en) | 13c-labeled eicosapentaenoic acid, its derivative and production thereof | |
Rodriguez et al. | Preterm infant formula supplementation with α linolenic acid and docosahexaenoic acid | |
Salem Jr et al. | Biosynthesis in Various Species and Compartments in vivo | |
Herman et al. | Quantitative determination of prostaglandins E1, E2 and E3 in frog tissue | |
JPH072724A (en) | 13c-labeled arachidonic acid and its derivative and method for producing the same | |
Vasdev et al. | Metabolism of erucic acid in the isolated perfused rat heart | |
JPH05246938A (en) | Heavy hydrogen labeled higher fatty acid | |
Croom et al. | Biotin deficiency and the fatty acids of certain biotin-requiring bacteria | |
Van et al. | Synthesis and identification of AceDoxyPC, a protectin-containing structured phospholipid, using liquid chromatography/mass spectrometry | |
Thompson et al. | Aspects of fatty acid metabolism in Galleria mellonella (L.)(Lepidoptera: Pyralidae): Isolation of the elongation system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20000530 |